MAIA Biotechnology CEO presents at Smart Diaspora 2025

MAIA Biotechnology (MAIA) announced a presentation by CEO Vlad Vitoc, M.D. at Smart Diaspora 2025, a conference dedicated to advancing oncology research and innovation in Romania. Dr. Vitoc noted Romania as the most recent country to begin screening patients for the expansion phase of its THIO-101 Phase 2 clinical trial which evaluates ateganosine sequenced with an immune checkpoint inhibitor as a third-line treatment for non-small cell lung cancer. “It is rewarding to bring MAIA’s Phase 2 expansion trial of our lead candidate to my home country, where NSCLC continues to challenge medical oncologists with limited treatment options. In third-line NSCLC patients who have become resistant to chemo and immunotherapy, current treatments have response rates of up to 6%. Our investigators are very excited about the observed 38% response rates from our treatment with ateganosine offering a compelling alternative for this large patient population,” said Dr. Vitoc. “By expanding our study to Romania, we are accelerating patient access to our innovative telomere-targeting therapy, and strengthening our strategy to pursue accelerated approval in the U.S. based on the FDA’s Fast Track Designation we received in July.”